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This paper addresses the use of systematic review and meta-analysis to evaluate the strength of evidence for health
benefits of probiotic foods, especially relating to health claim substantiation in the European Union. A systematic
review is a protocol-driven, transparent and replicable approach, widely accepted in a number of scientific fields,
and used by many policy-setting organizations to evaluate the strength of evidence to answer a focused research
question. Many systematic reviews have been published on the broad category of probiotics for many different
outcomes. Some of these reviews have been criticized for including poor quality studies, pooling heterogeneous
study results, and not considering publication bias. Well-designed and -conducted systematic reviews should address
such issues. Systematic reviews of probiotics have an additional challenge – rarely addressed in published reviews - in
that there must be a scientifically sound basis for combining evidence on different strains, species or genera. The
European Food Safety Authority (EFSA) is increasingly adopting the systematic review methodology. It remains to
be seen how health claims supported by systematic reviews are evaluated within the EFSA approval process. The
EFSA Panel on Dietetic Products, Nutrition and Allergies deems randomized trials to be the best approach to generating
evidence about the effects of foods on health outcomes. They also acknowledge that systematic reviews (with or
without meta-analyses) are the best approach to assess the totality of the evidence. It is reasonable to use these
well-established methods to assess objectively the strength of evidence for a probiotic health claim. Use of the
methods to combine results on more than a single strain or defined blend of strains will require a rationale that
the different probiotics are substantively similar, either in identity or in their mode of action.
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Probiotics are live microorganisms that, when adminis-
tered in adequate amounts, confer a health benefit on
the host [1]. Although probiotics can be administered in
different regulatory categories of products, this paper
focuses on probiotics used in foods. Probiotic foods
include yogurt, cheese, juices, and cereal bars among
others, the most common being yogurt. European Union
(EU) consumers have used probiotic foods for decades,
but with the implementation of EU legislation on health* Correspondence: mes@mesanders.com
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unless otherwise stated.claims starting in 2009, no specific health claims for pro-
biotic foods have been approved by the agency respon-
sible for reviewing health claim substantiation in the EU,
the European Food Safety Authority (EFSA). As a result,
at this point in time (September 2014), probiotic food
labels cannot communicate any health benefits to con-
sumers in the EU. Determining what level of evidence is
deemed sufficient to support health claims for probiotics
has been much debated in recent years [2-8]. In addition
to the lack of approved health claims for probiotics in
the EU, the European Commission has indicated that
the term “probiotic” in itself is an implied health claim,
and subsequently the term “probiotic” should not be
used on products in the absence of an approved healthl. This is an Open Access article distributed under the terms of the Creative
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or “active bacteria” have been banned as descriptors for
foods by some member states: Ireland [10] and Sweden
[11]. Therefore, no health claims can be made on pro-
biotic foods in the EU, even though evidence for health
benefits of probiotics mounts in the scientific literature
[12-16]. One reason for this seeming disparity is that
studies to substantiate health claims for foods must (1)
be conducted on subjects reflecting the general popula-
tion, and (2) target functional or reduction of disease
risk endpoints rather than therapeutic ones, [17] render-
ing some probiotic research ineligible to substantiate
food claims. The medical community may be less in-
clined to make such a distinction. For example, the
European Society for Primary Care Gastroenterology
[18], the World Gastroenterology Organisation [19] and
the European Society for Paediatric Gastroenterology,
Hepatology and Nutrition [20] have all published guide-
lines for probiotic use.
One tool that can provide the most objective assess-
ment of evidence on a given endpoint is a systematic
review (SR), with or without a meta-analysis (MA) (the
statistical combination of the results of the included
studies to provide an estimate of the size of an effect or
association). By systematically and rigorously identifying
and critiquing as much of the available evidence for a
pre-specified intervention, comparator and endpoint as
possible, an assessment of the relevant body of evidence
can be made. Based on this assessment, it may be
possible to draw conclusions about the strength of the
evidence for a specific intervention versus a specific
comparator. This is a well-established approach that has
been used in many fields including health and social care
[21] and has also been used to explore the benefits of
probiotics. Here, we review what is required for a well-
conducted systematic review to set the stage for discus-
sion of applying this method to assess evidence to
substantiate a health claim for a probiotic food.
Our focus is not to build a case for any specific
probiotic health claim, but to discuss the scientific basis
for appropriate application of the systematic review and
meta-analysis approach to assessing the totality within
the field of probiotics. Although the literature is replete
with meta-analyses where data on different strains and
probiotic preparations have been pooled, critics hold
that such techniques should be reserved for data on the
same probiotic strain or strain blend. We propose that
in certain well-considered situations, it is possible to
pool results on different probiotics. Developing a scien-
tific rationale based on substantial identity or common
modes of action may justify such an approach. Although
some probiotic functions are certainly strain-specific, we
suggest conversely that not all probiotics function differ-
ently. When it is possible to link different probioticstrains by a common mechanism of action, pooling data
on these strains may be appropriate.
What are systematic review and meta-analysis?
A SR is a review that follows a pre-specified protocol
to identify, select, critique, synthesize and summarize
evidence to answer a focused research question [22-24].
Generally, there are seven steps to a SR [22,24-30]:
Step 1: Framing the question
Step 2: Identifying potentially relevant studies
Step 3: Study selection
Step 4: Data extraction
Step 5: Quality assessment
Step 6: Synthesizing the evidence
Step 7: Interpreting the findings
In brief, the first step involves defining and refining a
research question [31] followed by the development of a
protocol that sets out in detail how the SR steps will be
conducted. The protocol presents the research question
in terms of the Population of interest, Intervention(s)
received by the population, Comparator interventions,
Outcome(s) (or endpoints), and Study types of interest.
This type of conceptual breakdown of the research ques-
tion is known as ‘PICOS’. It is generally recommended
that the protocol be peer-reviewed by external reviewers
and then registered (e.g., through the International Pro-
spective Register of SRs PROSPERO [32]. This is to
encourage adherence to the protocol and to maximize
transparency.
After the protocol is finalized, an extensive literature
search is undertaken to identify relevant studies, includ-
ing a search for both unpublished and published data,
preferably regardless of language. Next, study titles and
abstracts, and then full papers or unpublished reports
are screened for inclusion in the SR with inclusion deci-
sions made based on the defined ‘PICOS’. The data re-
quired to answer the review question are then extracted
from the included studies and the methodological qual-
ity of the studies is assessed. It is recommended that
study selection and data extraction are conducted by at
least two reviewers working independently in order to
minimize human error in making decisions about study
relevance and to maximize accurate reporting of the
data. To maximize consistency and reduce opportunities
for error, data extraction should be piloted within
spreadsheet or review software, by both reviewers, and
the agreed template used for all studies. Additional data
may be collected from the original researchers who
conducted the included studies [33].
Quality assessment of the included studies is a key
component of the SR process as it provides a view on
the reliability of the evidence reported in each of the
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risk of bias tools available [22,24,34-38] and they are
usually specific to the study type (i.e., a different quality
assessment tool asking different questions would be used
for randomized trials than for non-randomized observa-
tional studies).
Depending on the nature of the outcome data, the
results of SRs may be presented in a narrative and/or
quantitative synthesis. When it makes sense to combine
data from similar studies (i.e., when they have similar
participants, interventions and outcomes) it may be
possible to quantitatively synthesize the outcomes using
statistical techniques such as meta-analysis (MA). MA
pools results from different studies to obtain an average
estimate of effect across studies. In simple terms, studies
may be weighted so that larger studies have a greater
impact on the pooled result than smaller studies. This
method increases the statistical power to detect a differ-
ence in effect that may not be detected in individual
studies, and increases the precision of the estimate of
the effect of the intervention [22,24]. Inevitably, there
will be some variation in the estimated effects between
studies included in a MA. If the variation is significant
(statistically heterogeneous) subgroup analyses may be
conducted. Ideally these should be specified a priori in
the case of study characteristics that would be expected
to influence treatment effects. Subgroup analyses are
also used to explore inconsistencies between study re-
sults that are unlikely to have arisen by chance alone
[22]. Sensitivity analyses may also be conducted (for
example, omitting studies with lower quality from the
analysis) to give an indication of the ‘robustness’ of the
results [39]. Meta-regression is an extension to subgroup
analysis that evaluates continuous and categorical vari-
ables [24].
The last step of the SR process includes interpret-
ation of the findings in the context of the quality of the
body of evidence [24,27]. If the SR includes a MA, the
degree of consistency across studies should be consid-
ered to increase confidence in the pooled estimate of
effect [35]. Without knowing the consistency of the re-
sults between studies (i.e., the degree of heterogeneity),
it is impossible to determine the generalizability of the
estimate for the average effects [35]. At this stage, the
main results are also discussed within the context of
other (systematic) review evidence and any gaps in the
evidence.
When reporting a SR, transparent reporting of the
review methods and assumptions should be the main
objective. SRs should conform to reporting guidance
such as the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) framework [28].
Ideally, systematic reviews should also be subject to
peer review.Use of systematic review and meta-analysis methods in
assessing the effects of probiotics
The SR process is used in several arenas to assess the
evidence base in support of regulatory and policy recom-
mendations. Despite the robustness of SR methodology
for assessing a body of evidence, we identify four issues
relating to the use of meta-analysis in the field of
probiotics:
 Was the intervention defined appropriately?
 Was the search extensive and was publication bias
assessed? SRs which have not searched widely for
studies and which have not assessed publication bias
may produce biased results.
 Were results combined appropriately?
 Were analyses conducted to assess study quality?
SRs and MAs that do not explore the effect of
including lower quality studies run the risk of
providing unreliable results.
Was the intervention defined appropriately?
Defining the intervention can be a particular challenge
for SRs of probiotics, which comprise a broad range of
different genera, species and strains of live microbes. An
intervention, or the class of substance (such as a pro-
biotic) that is the subject of the review, does not have to
be a single substance. But in the case of grouping mul-
tiple substances into one class, there must be a sound
rationale that the members of the class as defined are
expected to function in a similar manner (Table 1). A
probiotic intervention may comprise a single strain or a
mixture of strains selected from a broad range of live
microorganisms, including prokaryotic and eukaryotic
microbes of different genera, species and strains. Com-
mon bacterial genera used as probiotics include Lactoba-
cillus, Bifidobacterium, Propionibacterium, Streptococcus
and Bacillus. Strains of the yeast, Saccharomyces cerevi-
siae (biovariant boulardii), are also used.
Observations by early researchers on probiotic
functionality, especially with regard to outcomes from
in vitro or animal studies, clearly indicate that different
strains of the same species may behave differently. Van
Hemert et al. [40] illustrate this point. They tested 42
Lactobacillus plantarum strains and found a 14-fold
difference in the strains’ ability to induce peripheral
blood mononuclear cells to secrete interleukin-10.
Similar strain-specific responses are seen in many other
in vitro and animal studies that assess biological prop-
erties of different probiotics. The body of literature in
human studies reveals few head-to-head comparisons
of probiotics. A few examples are available in the litera-
ture where different probiotic products or different
genera or species are compared. Canani et al. [41] com-
pared 5 different probiotic preparations with a placebo
Table 1 Criteria that may be acceptable* for combining different probiotic strains into the same ‘class of intervention’
for a specific outcome
Rationale Probiotic formulation defining
the intervention class
Example Comment
Common identity Single strain of one specific genus
and specie
L. acidophilus strain A All studies include the same strain;
may include studies conducted in
different food matrices
Common identity Single defined blend of multiple
strains (strains A + B + C)
L. acidophilus strain A
and L. casei strain B and
B. lactis strain C
Strains must be maintained in
equivalent relative doses in all
studies
Common taxonomy Studies used different strains of
same species or subspecies?
L. acidophilus strain A, L.
acidophilus strain B, or L.
acidophilus strain C
Different studies using different
strains included
Common structural or secreted product
(e.g., beta-glycosidases, exopolysaccharides)
Different strains from a defined
taxonomic group that may
include different species or genera
All strains of L. bulgaricus
and S. thermophilus
Different studies using different
strains included
Common mechanism of action known to be
necessary and sufficient for the effect (e.g.,
production of a specific bacteriocin or range of
bacteriocins known to be active against a specific
pathogen, or induction of immune mechanisms
needed for the effect)
Different strains from a defined
taxonomic group that may
include different species or genera
L. salivarius strain A Different studies using different
strains included
L. salivarius strain B
Common physiological effect previously proven
by at least one human study of quality
Different strains from a defined
taxonomic group that may
include different species or genera
All strains Different studies using different
strains included
*To the extent that commonalities cannot be defined for different probiotic strains, studies on them should not be pooled into a meta-analysis. For example,
probiotics such as Saccharomyces boulardii, Bacillus coagulans and Bifidobacterium species likely are too different biologically and mechanistically from each other
to form one class of intervention. Additionally, even if taxonomically similar, if different strains have different mechanisms responsible for an effect, it may be
inappropriate to pool studies. For example, a meta-analysis on anti-infective actions of probiotics likely should not pool data from a Lactobacillus rhamnosus strain
where effects are known to be due exclusively through immune enhancing activity in the small intestine and a Lactobacillus salivarius strain where effects are
known to be due primarily through bacteriocin production in the colon.
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effective in treating children with acute diarrhoea.
O’Mahony et al. [42] compared a Lactobacillus salivar-
ius strain and a Bifidobacterium infantis strain in sub-
jects with irritable bowel syndrome and found that only
the B. infantis strain significantly alleviated symptoms.
Such studies show that in some cases, different clinical
outcomes result from using different strains. However,
in other conditions, different strains of probiotics have
a similar impact on a particular clinical endpoint. This is
the case with necrotizing enterocolitis [43], antibiotic-
associated diarrhoea [14] and upper respiratory tract in-
fections [12], where SRs combining results of multiple
probiotic preparations resulted in convincing evidence of
efficacy for a broad range of probiotics. In these examples,
not all tested probiotics seemed equivalently effective, but
different probiotics were effective. In fact, many SRs pub-
lished on probiotics have tended to combine all probiotic
preparations, although criticism of this approach is build-
ing [19]. Some SRs that have included a wide range of
probiotic strains conclude that not all strains are equally
effective [44]. A few SRs have focused on single strains,
such as L. rhamnosus GG [45,46], S. boulardii [47] or L.
reuteri [48].
A scientific justification may exist for grouping mul-
tiple strains, species or even genera of probiotics intoone class of intervention for the purpose of conducting
a SR and MA. It may be appropriate to group multiple
strains of a narrow taxonomic cluster, such as Bifidobac-
terium animalis subsp. lactis where evidence shows little
diversity in the members of this subspecies. Lee and
O’Sullivan state that four strains of B. animalis subsp.
lactis exhibited >99% sequence identity over their entire
genomes, indicating a very closely related group [49].
Masco et al. [50] have also shown that based on pulsed-
field gel electrophoresis, all commercial B. lactis strains
are indistinguishable. Barrangou et al. [51] also found a
high degree of genome conservation indicative of a
monomorphic subspecies. Collado et al. [52] showed
that 7 of 8 B. lactis strains had essentially the same
strain-specific pattern as indicated by a random ampli-
fied polymorphic DNA technique. Such taxonomic
grouping may, however, be criticized in the absence of
information on the mechanism of action for the benefit,
since it is possible that the part of the genome that is
not shared encodes the functional activity.
It may also be appropriate to propose that several pro-
biotics might be legitimately grouped based on the pro-
duction of common “structures”, such as peptidoglycan,
flagellae or exopolysaccharides, known to evoke specific
physiological responses in the host or could be grouped
based on a common mechanism of action. This latter
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ing lactose digestion is linked to the microbial produc-
tion of beta-galactosidase. EFSA approved the health
claim that “yogurt cultures” (which encompass any
strains from the species Lactobacillus bulgaricus and
Streptococcus thermophilus) could improve lactose diges-
tion [53]. Note that this claim does not extend to the
Lactobacillus genus, as mixed results have been reported
among other tested Lactobacillus species. In another
example, it is conceivable that a class could be defined
as members of a specific taxonomic cluster that also
produce certain levels of a certain metabolite in vivo,
such as specific short chain fatty acids.
When clustering different probiotics into one inter-
vention group, the conclusions of the SR could only
apply to the intervention class as defined. Therefore, if
the intervention was defined as the subspecies, B. ani-
malis subsp. lactis, rather than B. animalis subsp. lactis
strain Bb-12, for example, then the conclusions of the
SR would apply to all strains of B. animalis subsp. lactis,
whether tested in a human study or not. This concept
has already been accepted by EFSA in the case of yogurt
cultures. The presumption that any benefits apply only
to the individual strains used in the included studies
reflects a lack of conviction by those defining the class
as the subject of the SR that the class is logically and
appropriately defined. Where strains express unique
characteristics (not common to their genera or species)
that enable a specific health benefit, they should not be
grouped in a MA since results from one strain cannot
inform (or predict) effects of another strain of the same
genus or species. However, if there is a scientifically
sound basis for defining a class that encompasses differ-
ent strains, information on all members of that class can
be used to provide a more comprehensive set of sup-
porting data. If a study does not show an effect for one
of the strains in the class, this may simply represent a
study with null results, some of which will be expected
in any body of research. If a strain is not represented in
the collection of reviewed studies, it also does not mean
that it should be excluded from the general conclusions
on the benefit or otherwise of that class. Alternatively,
subgroup analysis that shows efficacy for specific mem-
bers of the defined class may enable researchers to refine
the class more narrowly. Of note to this discussion is
that in theory, EFSA accepts pooling data from studies
of a well-defined food constituent that is responsible for
a claimed effect when given at the appropriate dose [54].
However, if pooling data on different probiotic products
(comprising different strains), we reiterate that it will be
necessary to provide a scientific justification for consid-
ering this group as a defined class.
Challenges emerge if one intends to use pooled data
from studies on different strains clustered into oneintervention group as part of a dossier to substantiate an
EU health claim. One pillar of such a dossier is
characterization of the substance under consideration.
This section clearly defines what food or food ingredient
is the subject of the health claim. EFSA requires that
characterization is very specific. A strategy for definition
of the substance under review must be developed if data
from different strains, potentially delivered in different
matrices, are to be combined in a MA. It is possible that
a SR for a defined set of probiotics can be used as evi-
dence for a dossier for one specific member of that class.
Then the characterization information should be specific
for that one member.Was the search extensive and was publication bias
assessed?
Although the SR might be useful to bring the studies
together, the MA should not be undertaken when there
is likely to be serious publication bias, since this is likely
to provide an unreliable estimate of the true effect size
[24]. Publication bias occurs when publication is influ-
enced by the results. An extensive search for both pub-
lished and unpublished data and the use of a range of
different search techniques mitigates this issue, but rele-
vant studies may still remain inaccessible to specific
reviews. This is why investigations of publication bias,
where possible, are helpful in revealing the possible ex-
tent of missed studies and the potential for risk of publi-
cation bias should be considered within the conclusions
of a SR [55]. Prospective trial registries such as Clinical-
Trials.gov improve awareness of research that has been
undertaken and already includes numerous probiotic
trials.Were studies combined appropriately?
When deciding whether to conduct a MA, input from a
topic expert is often helpful to ascertain whether it is ap-
propriate to combine the results of the identified studies
[24]. Current guidance recommends that data should
not be pooled when there is a mix of different compari-
sons of different treatments, or when the outcomes are
too diverse (i.e., when they measure different variables)
[24]. In the case of probiotics, this guidance would not
preclude combining studies on different probiotic prod-
ucts as long as there is a solid scientific rationale for
grouping the different probiotics into one class. As an
extension to this, it may be misleading to combine re-
sults in a MA if there are substantial differences between
study estimates of effect, particularly if they are in
opposing directions [22]. If this occurs with probiotics
studies, the studies could be grouped into logical sub-
sets, for example by probiotic strain, species, or genera
(defined a priori).
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MAs of poor quality studies may result in an erroneous
interpretation [24]. Different methods have been sug-
gested to deal with this potential problem, such as only
including high quality studies in a review, or conducting
sub-group analyses, or sensitivity analysis by quality
criteria, to allow a focus on the higher quality studies.
Quality assessment may reflect concerns about study
methods, but may also take into account other aspects
of the study such as concerns about bias caused by the
funding of the research or inadequate information about
the study as a result of the publication format (in the
case of conference abstracts). The inclusion of only poor
quality studies in MA (or where a high proportion of the
weight of the evidence is from poor quality studies)
should be avoided, as they may cast doubt on any
subsequent conclusions, or even hinder any correct
interpretation.
Use of the systematic review/meta-analysis process by
the European Food Safety Authority
In 2010, EFSA published its guidance on the conduct of
SRs of relevance to food and feed safety [23]. EFSA
noted that, although rarely used in these areas, SR
methods had potential for application in the fields of
food and feed safety. In 2012, EFSA advertised a series
of framework agreements (Scientific Services to Support
EFSA Systematic Reviews) [56] with suppliers to provide
training in SR methods, to offer expert support at vari-
ous stages of the SR process and to provide SRs to
EFSA. Suppliers were requested to perform SRs in line
with the methods described in the EFSA framework
agreements [56].
The EFSA guidance [23] clearly stresses the import-
ance of precisely defined, closed-framed questions (ex-
posure or intervention, diagnostic accuracy, descriptive
questions of populations or systems), which are captured
a priori in clear eligibility criteria for studies to be in-
cluded in the review.
In cases where there is a large quantity of evidence, the
SR method can formally and systematically summarize
that evidence (with MA where data permit) and provide
more precise estimates of effects than an individual
study can provide. The value of the SR approach also
lies in its presentation of all of the available evidence
with an assessment of the quality of that evidence: the
strengths and limitations of the evidence base can thus
be seen in a clearer way. The more controversial the
topic, the more important it is for the SR process to be
described in detail, so that the methods can be under-
stood and alternative approaches discussed. The EFSA
guidance provides a clear outline of a suitable process
for conducting a SR and some recommendations on the
reporting of a SR, without providing a formal reportingstructure such as the PRISMA guidance described
earlier. In the recent framework tender documents [56],
suppliers are asked to consider documenting and report-
ing the method and results of the SR using the PRISMA
statement and, where that is not applicable, to docu-
ment and explain any discrepancies from the PRISMA
statement.
The use of MA within SRs is guided by the suitability
of the data for pooling; the considerations informing a
decision to use MA are described in Appendix E of the
EFSA guidance [23]. Although this is not a formal
recommendation of the EFSA guidance, the presentation
of the issues around MA in the guidance suggests that
for SRs to be as transparent as possible, the rationale
and justification for MA should be presented in the SR
report. The discussion and conclusions of the SR should
be grounded in the a priori objectives for the SR and the
results identified. Again, adhering to this approach and
documenting the rationale in full will contribute to the
rigour and objectivity of a particular SR.
Use of the systematic review and meta-analysis for
evaluation of evidence to substantiate health claims on
foods in the European Union
In Europe, Article 6 of EC Regulation 1924/2006 states
that health claims for food labeling must be based on
and substantiated by ‘generally accepted scientific evi-
dence’ [57]. In order to ensure that health claims made
are truthful and can be understood by consumers, health
claims undergo a specific procedure of assessment and
authorization involving consultation to the EFSA Panel
on Dietetic Products, Nutrition and Allergies (NDA
Panel) [57]. For the assessment of all types of health
claim applications (article 13.1, 13.5 or 14), the NDA
Panel considers whether the beneficial effect of the food
is substantiated by generally accepted scientific evidence
[57] using an assessment process of the highest possible
standard. As described by the NDA Panel, this involves
taking into account the totality of the available scientific
data, and weighing the evidence obtained from individ-
ual studies [57].
The EFSA ‘General guidance for Article 13.1, 13.5 and
14 health claims evaluation’ [57] indicates that data from
intervention and observational studies in humans should
be presented with the most reliable data being assessed
according to a hierarchy of study designs. Trials with full
randomization and adequate allocation concealment
(method of randomization reported) are deemed to be at
the top of the hierarchy of human intervention studies
for assessing a cause-effect relationship between the
consumption of the food or food constituent and the
claimed health effect [58]. Cohort studies are considered
to be at the top of the hierarchy for human observa-
tional studies [58].
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how many or what type of studies are needed to sub-
stantiate a claim, the reproducibility of the effect of the
food as indicated by consistency between studies is an
important consideration for their final assessment. Thus,
a comprehensive review of the data from human studies
addressing the specific relationship between the food
and the claimed effect is required from the applicant.
The NDA panel guidelines make it clear that in evalu-
ating and weighing the evidence to substantiate health
claims on foods, SR and MA can play an important role
[58]. EFSA ask applicants to provide a comprehensive
review in order to evaluate the totality of the evidence
proposed in the dossier. This step must be included as a
specific section of a health claim dossier. The NDA
panel’s final opinion will be based on a SR of the totality
of the available data, but does not require that all indi-
vidual randomized trials or other type of studies show
statistical significance. For example, when considering
the evidence for periconceptional folate supplementation
for preventing birth defects, 5 randomized trials were
considered [59]. Since the incidence of birth defects was
quite low, the MA process allowed pooling of available
data to reach a convincing conclusion about the effect-
iveness of folate. The MA reached a level of evidence
that was not reached by the individual randomized trials.
The NDA panel does require that the SR provides
convincing evidence on the consistency and reproduci-
bility of the effect when analyzing the totality of the data.
EFSA considers randomized trials as the best tools to
generate evidence on the effects of interventions and
considers SR and MA to be the best tools to evaluate
the totality of the evidence and inform a final opinion.
MA and SR may be useful to address the following
scenarios that we envision could emerge in submitted
dossiers:
 Studies are underpowered due to a smaller effect
size than predicted, so none of the studies reaches
statistical significance. But, when data are analyzed
together as part of a MA, a statistically significant
average result is obtained.
 One pivotal study has been conducted which is in
favor of the intervention, and other studies with null
results have been published. This reflects a genuine
evidence base and the review of all contributing
studies should allow exploration of heterogeneity
and provide information on the true direction and
size of the health benefit. All studies, with all results,
contribute to an overall picture of the effect.
 Studies are underpowered due a heterogeneous
population within each study, comprising
responders and non-responders, which cancel each
other out in the analysis of the individual study. Thebest approach to this situation is to better identify
the target population a priori and perform randomized
trials with the appropriate population subset, or to
unpick the studies into the relevant subgroups. On
the other hand, acceptance of the health claim has
the potential to benefit a subset of the population
consuming the product, which is of benefit to those
consumers. Subgroup analyses defined a priori may
enable identification of the responding subgroup
and convincing evidence in support of a claim for
the subgroup may be revealed.
 The incidence of the health endpoint is low (such as
incidence of flu during the winter season) and very
large sample sizes among the study population are
required. Such sample sizes are better achieved by
pooling the results of several randomized trials,
providing that these studies collectively provide
sufficient power.
 Many statistically significantly positive randomized
trials exist, but no two trials investigate the same
strain. If there is a scientifically valid basis to expect
that a group of different strains would function
similarly on an endpoint, then they can be
reasonably grouped into one intervention for a
meta-analysis, and the resulting meta-analysis would
be sufficient evidence to support a health claim.
We recognize that SRs are only one input to a
decision-making process regarding formulation of policy
derived from evidence. The health technology assessment
process, for example, also considers information on the
economic and legal aspects of competing interventions.
Conclusions
SR and MA are transparent and rigorous approaches to
synthesizing evidence. It is widely accepted in many
scientific disciplines and by many policy-setting organi-
zations as the best way to evaluate the strength of
evidence available to answer a focused question. EFSA
guidance acknowledges the validity of well-conducted
SRs for closed-framed questions, which seems appropri-
ate for assessing evidence for probiotics: In population P,
does intervention I affect outcome O when assessed using
comparator C?
EFSA endorses the SR process to inform their judg-
ment when deciding health claims, as observed with the
decision on maternal folate intake and reduced risk of
neural tube defects. This suggests the method is also
suitable for probiotic health claims.
Applying the SR approach to probiotics to obtain
evidence on a single strain (e.g., Strain A) or on a single,
defined multi-strain probiotic (e.g., Strain A + B + C) is
scientifically justifiable. Applying the SR approach to
studies conducted on a broader range of probiotics (i.e.,
Glanville et al. Nutrition Journal  (2015) 14:16 Page 8 of 9studies of different strains of the same species or subspe-
cies, different species or different genera, such that study
1 is conducted on strain A, study 2 is conducted on
strain B, study 3 is conducted on strain C + D) requires a
scientifically valid justification for definition of the class.
However, EFSA precedent has allowed such ‘clustering’
of all yogurt cultures into a category of food that can
improve lactose digestion, even though the possibility
exists that a particular strain may not deliver adequate
lactase to improve lactose digestion. EFSA seems to
recognize that available evidence provides a reasonable
certainty that yogurt cultures will provide this benefit.
However, 100% certainty is not possible and should not
be required.
The majority of SRs published on probiotics to date
has been conducted on a broad group of live microor-
ganisms without stated justification for clustering into
one class. In many cases, this includes studies using
Lactobacillus, Bifidobacterium, E. coli, Saccharomyces
and others. If the overall effect is positive, the conclusion
from such reviews has generally been that ‘probiotics’
are effective for the particular indication. However, they
have not concluded that every possible probiotic strain
will necessarily be effective, and they have generally
acknowledged that effects may be due to only specific,
tested strains. A strict application of the SR approach
should enable application of the conclusions of the
review to every member of the class as defined.
Procedures within EFSA, including their approach to
definition and characterization of the substance under
review, presents a challenge for use of the SR and MA
approaches on a defined class of different strains of
probiotics for primary health claim substantiation.
In conclusion, SR and MA represent a well-developed
and widely applied means to evaluate the strength of
research evidence and should be acceptable by EFSA for
substantiating probiotic claims. Use of SR to combine
studies on multiple probiotic strains, however, requires
a valid scientific rationale that combining evidence
from different strains is biologically and physiologically
justified.
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